Puma Biotechnology Inc (PBYI) Given Buy Rating at Barclays PLC

Barclays PLC reissued their buy rating on shares of Puma Biotechnology Inc (NYSE:PBYI) in a research note issued to investors on Friday morning. The brokerage currently has a $122.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $103.00.

Other equities analysts have also issued research reports about the company. J P Morgan Chase & Co reissued a buy rating on shares of Puma Biotechnology in a research note on Tuesday, August 1st. BidaskClub lowered Puma Biotechnology from a strong-buy rating to a buy rating in a research report on Thursday, August 10th. Citigroup Inc. reaffirmed a buy rating and set a $114.00 price target on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Stifel Nicolaus reaffirmed a buy rating and set a $118.00 price target (up previously from $105.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Finally, Bank of America Corporation reaffirmed a buy rating and set a $117.00 price target (up previously from $100.00) on shares of Puma Biotechnology in a research report on Friday, July 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $130.67.

Puma Biotechnology (NYSE PBYI) traded down $24.20 during trading hours on Friday, reaching $103.00. The company’s stock had a trading volume of 5,677,100 shares, compared to its average volume of 1,118,516. Puma Biotechnology has a 1 year low of $28.35 and a 1 year high of $136.90.

Puma Biotechnology (NYSE:PBYI) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating the consensus estimate of ($2.50) by $0.43. The company had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same period in the previous year, the company posted ($1.11) EPS.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/12/puma-biotechnology-inc-pbyi-given-buy-rating-at-barclays-plc.html.

In related news, SVP Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $100.09, for a total value of $1,501,350.00. Following the sale, the senior vice president now owns 28,239 shares of the company’s stock, valued at approximately $2,826,441.51. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 22.70% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in PBYI. Parametric Portfolio Associates LLC acquired a new stake in Puma Biotechnology in the 1st quarter valued at approximately $257,000. Teachers Advisors LLC raised its position in Puma Biotechnology by 2.0% in the 1st quarter. Teachers Advisors LLC now owns 145,197 shares of the biopharmaceutical company’s stock valued at $5,401,000 after buying an additional 2,824 shares during the last quarter. Legal & General Group Plc raised its position in Puma Biotechnology by 2.8% in the 1st quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 249 shares during the last quarter. Vanguard Group Inc. raised its position in Puma Biotechnology by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 2,428,909 shares of the biopharmaceutical company’s stock valued at $90,355,000 after buying an additional 101,722 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Puma Biotechnology by 17.3% in the 1st quarter. Geode Capital Management LLC now owns 232,371 shares of the biopharmaceutical company’s stock valued at $8,644,000 after buying an additional 34,190 shares during the last quarter. 80.98% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply